Geode Capital Management, LLC Viracta Therapeutics, Inc. Transaction History

Geode Capital Management, LLC

$1.21 Trillion
Q3 2024

A detailed history of Geode Capital Management, LLC transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 250,007 shares of VIRX stock, worth $62,501. This represents 0.0% of its overall portfolio holdings.

Number of Shares

250,007

Previous 270,773 7.67%

Holding current value

$62,501

Previous $146,000 60.96%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$0.21 - $0.56 $4,360 - $11,628	-20,766 Reduced 7.67%	250,007 $57,000
Q2 2024 Aug 09, 2024	BUY	$0.5 - $1.17 $9,036 - $21,144	18,072 Added 7.15%	270,773 $146,000
Q3 2023 Nov 13, 2023	BUY	$1.03 - $1.58 $29,110 - $44,655	28,263 Added 12.59%	252,701 $262,000
Q4 2022 Feb 13, 2023	BUY	$1.26 - $4.38 $8,192 - $28,478	6,502 Added 2.98%	224,438 $327,000
Q3 2022 Nov 14, 2022	BUY	$3.32 - $5.69 $47,489 - $81,389	14,304 Added 7.02%	217,936 $930,000
Q2 2022 Aug 12, 2022	SELL	$1.87 - $5.0 $520,033 - $1.39 Million	-278,093 Reduced 57.73%	203,632 $790,000
Q1 2022 May 13, 2022	BUY	$2.23 - $4.76 $45,710 - $97,570	20,498 Added 4.44%	481,725 $2.29 Million
Q4 2021 Feb 11, 2022	SELL	$3.37 - $7.91 $67,649 - $158,785	-20,074 Reduced 4.17%	461,227 $1.68 Million
Q3 2021 Nov 12, 2021	BUY	$7.84 - $12.53 $251,389 - $401,774	32,065 Added 7.14%	481,301 $3.86 Million
Q2 2021 Aug 13, 2021	BUY	$7.55 - $12.95 $2.95 Million - $5.06 Million	390,701 Added 667.47%	449,236 $5.09 Million
Q1 2021 May 12, 2021	BUY	$7.58 - $18.67 $443,695 - $1.09 Million	58,535 New	58,535 $541,000

Others Institutions Holding VIRX

# of Institutions

Shares Held

5.63M

Call Options Held

Put Options Held

View Full List

About Viracta Therapeutics, Inc.

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $9.39M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

More about VIRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Viracta Therapeutics, Inc. Transaction History